Última actualización 24 de agosto de 2026
Key finding
Serum irisin level significantly declined from baseline (3.22 ± 0.53 ng/mL vs. 3.35 ± 0.64 ng/mL, P = 0.031)
This study investigated the effects of exenatide treatment on serum irisin levels in patients with type 2 diabetes mellitus (T2DM), finding a significant decline in irisin levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of exenatide treatment on serum irisin levels in patients with type 2 diabetes mellitus (T2DM), finding a significant decline in irisin levels.
Understanding how exenatide affects irisin levels can help clinicians better manage T2DM. The decline in irisin may have implications for cardiovascular health, as it was associated with changes in cholesterol levels, which are crucial for reducing heart disease risk in diabetic patients.
The study's sample size and population characteristics may limit generalizability. No significant associations were found between irisin levels and glycemic control parameters. The effectiveness of exenatide on irisin levels remains unclear due to limited evidence.
Published in
Publication details and source links for this paper.
Yuting G, Xiaoyu H, Kun Y, et al. Serum irisin level declines during exenatide treatment in patients with T2DM. Journal of Clinical & Translational Endocrinology. 2026;45:100447. doi:10.1016/j.jcte.2026.100447
Serum irisin levels significantly declined from baseline (3.22 ± 0.53 ng/mL vs. 3.35 ± 0.64 ng/mL, P = 0.031).
Change in irisin levels was positively associated with HDL-C levels (r = 0.154, P = 0.035).
Change in irisin levels was negatively associated with triglyceride levels (r = -0.159, P = 0.029).
Change in irisin levels was negatively associated with the TG/HDL-C ratio (r = -0.172, P = 0.018).
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Exenatide and Change in serum irisin level, Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels, HDL cholesterol, and 2 more.
This study contributes evidence to
Primary intervention
Exenatide
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
65
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Intervención
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Exenatide → Change in serum irisin level
Exenatide → Change in serum irisin level
Exenatide → Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels
Exenatide → Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels
Exenatide → Nonfasting Plasma Triglyceride Levels
Exenatide → Nonfasting Plasma Triglyceride Levels
Exenatide → Triglyceride-to-HDL cholesterol ratio
Exenatide → Triglyceride-to-HDL cholesterol ratio
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on GLP-1 Receptor Agonists and Adipokine and Angiogenic Markers, GLP-1 Receptor Agonists and Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels.
This study contributes to the evidence on the following intervention-outcome relationships.
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies on GLP-1 Receptor Agonists
Contributes to GLP-1 Receptor Agonists evidence base.
All studies measuring Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels
Measures Clinical parameters including blood pressure, glycemic control, and LDL cholesterol levels as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
GLP-1 Receptor Agonists may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
HDL cholesterol
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | moderate positive | ConsistencyScore™ Mixed | 1 study
Why this answer: This answer is based on 10 supporting studies with consistent results and a positive effect signal.
Limitations
Exenatide appears to improve Change in serum irisin level.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Change in serum irisin level
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Exenatide appears to improve Nonfasting Plasma Triglyceride Levels.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Nonfasting Plasma Triglyceride Levels
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Exenatide appears to improve Triglyceride-to-HDL cholesterol ratio.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Triglyceride-to-HDL cholesterol ratio
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
